Biogen (BIIB) had its price target raised by HC Wainwright from $228.00 to $237.00. They now have a "buy" rating on the stock.
Biogen (BIIB) had its price target raised by Wedbush from $187.00 to $191.00. They now have a "neutral" rating on the stock.
Biogen (BIIB) had its price target raised by Oppenheimer Holdings, Inc. from $250.00 to $275.00. They now have an "outperform" rating on the stock.
Biogen (BIIB) had its price target raised by Canaccord Genuity Group Inc. from $230.00 to $245.00. They now have a "buy" rating on the stock.
Biogen to acquire Apellis Pharmaceuticals for $5.6B, adding C3 therapies to portfolio [Yahoo! Finance]